94 related articles for article (PubMed ID: 24528512)
1. Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database.
Issa DE; Gelderblom H; Lugtenburg PJ; van Herk-Sukel MP; Houweling LM; De La Orden M; van der Werf-Langenberg ME; Nortier JW; de Jong FA
Eur J Cancer Care (Engl); 2015 Mar; 24(2):232-41. PubMed ID: 24528512
[TBL] [Abstract][Full Text] [Related]
2. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.
Li S; Liu J; Bowers C; Garawin TAFS; Kim C; Bensink ME; Chandler DB
Support Care Cancer; 2020 Jan; 28(1):113-122. PubMed ID: 30993450
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.
Dulisse B; Li X; Gayle JA; Barron RL; Ernst FR; Rothman KJ; Legg JC; Kaye JA
J Med Econ; 2013; 16(6):720-35. PubMed ID: 23452298
[TBL] [Abstract][Full Text] [Related]
4. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
[TBL] [Abstract][Full Text] [Related]
5. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
6. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.
Wang L; Barron R; Baser O; Langeberg WJ; Dale DC
Value Health; 2014 Sep; 17(6):739-43. PubMed ID: 25236998
[TBL] [Abstract][Full Text] [Related]
7. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
[TBL] [Abstract][Full Text] [Related]
8. Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle.
Li X; Luthra R; Morrow PK; Fisher MD; Reiner M; Barron RL; Langeberg WJ
J Oncol Pharm Pract; 2016 Oct; 22(5):679-89. PubMed ID: 26378158
[TBL] [Abstract][Full Text] [Related]
9. Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis.
Pettengell R; Schwenkglenks M; Bacon P; Lawrinson S; Duehrsen U
Hematol Oncol; 2011 Dec; 29(4):177-84. PubMed ID: 21246591
[TBL] [Abstract][Full Text] [Related]
10. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
11. [Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database].
Freyer G; Scotte F; Borget I; Bruyas A; Vainchtock A; Chouaid C
Bull Cancer; 2016 Jun; 103(6):552-60. PubMed ID: 27233367
[TBL] [Abstract][Full Text] [Related]
12. Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice.
Weycker D; Danel A; Marciniak A; Bendall K; Lipsitz M; Pettengell R
BMC Cancer; 2012 Aug; 12():362. PubMed ID: 22913768
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
[TBL] [Abstract][Full Text] [Related]
14. Risk of mortality in patients with cancer who experience febrile neutropenia.
Lyman GH; Michels SL; Reynolds MW; Barron R; Tomic KS; Yu J
Cancer; 2010 Dec; 116(23):5555-63. PubMed ID: 20715160
[TBL] [Abstract][Full Text] [Related]
15. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
16. The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.
O'Brien C; Fogarty E; Walsh C; Dempsey O; Barry M; Kennedy MJ; McCullagh L
Eur J Cancer Care (Engl); 2015; 24(1):125-32. PubMed ID: 24472035
[TBL] [Abstract][Full Text] [Related]
17. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
[TBL] [Abstract][Full Text] [Related]
18. Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study.
Noga SJ; Choksi JK; Ding B; Dreiling L; Ozer H
Clin Lymphoma Myeloma; 2007 May; 7(6):413-20. PubMed ID: 17621407
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
20. Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations.
Faqeer NA; Mashni O; Dawoud R; Rumman A; Hanoun E; Nazer L
J Clin Pharmacol; 2017 Feb; 57(2):275-279. PubMed ID: 27479828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
